Hepatocellular Carcinoma (HCC) Clinical Trial Monitor — Liver Cancer Pipeline Daily

The HCC trial landscape in 2026

Hepatocellular carcinoma is one of the most commercially competitive solid tumor settings. The atezolizumab plus bevacizumab approval (IMbrave150) reset the first-line standard of care, triggering a wave of combination immunotherapy trials that continues to mature. Durvalumab plus tremelimumab (HIMALAYA) added a second approved first-line regimen. Now, the competitive focus has shifted to second-line options after IO failure, adjuvant settings following resection or ablation, and novel mechanisms including anti-TIGIT, anti-LAG-3, and the emerging class of liver-targeted ADCs.

For oncology BD, medical affairs, and investment professionals, the HCC pipeline requires continuous monitoring. New Phase 2 data emerges monthly, Phase 3 readouts drive valuation events, and early Phase 1 entries signal which mechanisms are attracting capital and development resources.

Key HCC program categories to monitor:

• First-line combinations: IO + anti-VEGF combinations competing with atezolizumab/bevacizumab and durvalumab/tremelimumab
• Second-line after IO failure: Regorafenib, cabozantinib, and novel agents for patients who progressed on first-line IO
• Adjuvant/perioperative: Atezolizumab, nivolumab, and next-generation IO in resected or ablated early HCC
• Novel checkpoints: Anti-TIGIT (tiragolumab), anti-LAG-3, anti-TIM-3, and CTLA-4/PD-1 bispecifics
• Liver-targeted ADCs: Programs exploiting GPC3, AFP, CLDN6, and other HCC-enriched antigens
• Locoregional combination: Systemic IO plus TACE/TARE in intermediate-stage HCC

What DataLookout monitors for HCC

Configure your profile with keywords as specific or broad as your intelligence needs require. Examples:

• By line/setting: "advanced HCC", "unresectable hepatocellular carcinoma", "adjuvant HCC", "resectable liver cancer"
• By mechanism: "PD-L1 hepatocellular", "VEGF liver cancer", "GPC3 HCC", "TIGIT hepatocellular"
• By agent class: "TKI HCC", "immunotherapy liver cancer", "antibody-drug conjugate hepatocellular"
• Phase filter: Phase 3 for competitive intelligence, all phases for complete pipeline visibility
• By sponsor: Track AstraZeneca, Roche/Genentech, Bristol Myers Squibb, Merck, or smaller innovators in the ADC and targeted space

How it compares to ClinicalTrials.gov native alerts

ClinicalTrials.gov's notification system is inadequate for professional HCC monitoring:

• No mechanism filtering — TKIs, IO agents, ADCs, and locoregional therapy trials appear undifferentiated
• No phase filtering — Phase 1 dose-escalation studies appear alongside pivotal Phase 3 trials
• No change detection — updates to existing trial records (enrollment completions, status changes, site additions) are not surfaced
• No digest formatting — raw individual notifications with no context or prioritization
• Interface designed for patient discovery, not competitive or business development intelligence

DataLookout delivers a filtered daily digest — the professional intelligence layer on top of raw registry data.

Who uses HCC trial monitoring

Oncology business development teams

Companies with liver cancer franchises or developing IO combinations monitor HCC trial activity continuously. With AstraZeneca, Roche, BMS, Merck, and Gilead all active in the HCC IO space, understanding the competitive Phase 3 landscape is essential for licensing and co-development decisions. The locoregional combination space (IO plus TACE/TARE) is particularly active, with multiple sponsors vying to establish the standard of care for intermediate-stage HCC.

Healthcare fund analysts

Analysts covering oncology use HCC trial registrations as leading indicators for companies with liver cancer programs. A Phase 3 start for a GPC3-targeting ADC or an adjuvant Phase 3 IO trial can precede significant valuation events. Daily monitoring ensures no registration is missed before it becomes investor news.

Medical affairs and clinical development professionals

Medical affairs teams at HCC-focused companies track competitor trials to anticipate label changes, prepare for new entrants, and inform key opinion leader strategy. In a field where the treatment algorithm continues to evolve from one approved regimen to multiple competing options, real-time competitive awareness is essential.

Current HCC trial activity (as of March 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

Phase	Recruiting Trials	Key Sponsors
Phase 3	37	AstraZeneca, Roche, BMS, Merck, Gilead
Phase 2	128	Akeso, Innovent, Zymeworks, NCI, academic centers
Phase 1 / Phase 1–2	~50	NCI, emerging biotechs, ADC developers
Total recruiting	156	~80 industry-sponsored

The first-line IO combination space is consolidating. AstraZeneca has multiple Phase 3 trials running in HCC including studies combining durvalumab with novel agents beyond tremelimumab. Roche's TIGIT inhibitor tiragolumab is being tested in combination with atezolizumab plus bevacizumab in earlier-line settings. Gilead's magrolimab (anti-CD47) has an HCC program after its success in hematologic malignancies.

The ADC wave is arriving in HCC. GPC3 — highly expressed on hepatocellular carcinoma cells — is the primary target, with multiple GPC3-targeting ADCs from Chinese and Western biotechs entering Phase 1 and early Phase 2. Akeso's bispecific PD-1/VEGF antibodies have generated compelling Phase 2 data, driving multiple Phase 3 initiations in the HCC setting.

The adjuvant HCC space is particularly active following the phase 3 data supporting adjuvant atezolizumab. Multiple programs are studying adjuvant IO combinations in patients who have undergone surgical resection, ablation, or locoregional therapy — a setting with fewer treatment options and lower competition than advanced HCC.

Frequently asked questions

How current is the HCC trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated as sponsors register new trials or submit protocol amendments, typically within 24–48 hours.

Can I track HCC trials by treatment class (immunotherapy vs. TKI vs. ADC)?

Yes. You can configure keyword profiles for specific mechanisms — for example, "HCC PD-L1", "hepatocellular VEGF", "GPC3 ADC HCC", or "liver cancer TKI" — each delivering a focused daily digest on the specific programs you track.

Does DataLookout cover early-stage HCC trials as well as advanced disease?

Yes. You can filter by disease stage using keywords like "resectable HCC", "early hepatocellular carcinoma", "adjuvant HCC", or "Barcelona Clinic Liver Cancer stage" alongside phase filters.

How is DataLookout different from ClinicalTrials.gov alerts for HCC?

ClinicalTrials.gov offers basic email notifications without phase filtering, mechanism filtering, or digest formatting. DataLookout delivers a filtered, labeled daily digest — the professional intelligence layer on top of raw registry data. You get only the trials that match your specific keywords, phase, and sponsor criteria.